Gut bacteria may predict immunotherapy success in bladder cancer

NCT ID NCT04566029

First seen Jan 05, 2026 · Last updated May 05, 2026 · Updated 15 times

Summary

This study explored whether the proteins from gut bacteria differ between bladder cancer patients who respond to immunotherapy and those who do not. Researchers collected stool and blood samples from 40 patients to compare these protein profiles. The goal was to find a way to predict which patients will benefit from treatment, avoiding unnecessary side effects and costs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre Antoine Lacassagne

    Nice, 06189, France

  • Centre Leon Berard

    Lyon, 69373, France

  • HEGP GH Universitaire Paris Ouest

    Paris, 75908, France

  • Hopital Tenon ( Paris)

    Paris, Paris Cx 20, 75970, France

  • ICANS Strasbourg

    Strasbourg, 67091, France

  • ICM parc euromedecine

    Montpellier, Hérault, 34298, France

  • ICO-Site Paul Papin

    Angers, 49055, France

  • Institut Bergonié

    Bordeaux, 33076, France

  • Institut Sainte Cancerologie Lucien Neuwirth

    Avignon, Saint Priest En Jarez, 42271, France

  • Iuct Oncopole

    Toulouse, 31059, France

Conditions

Explore the condition pages connected to this study.